Paying user area
Try for free
Celgene Corp. pages available for free this week:
- Statement of Comprehensive Income
- Balance Sheet: Assets
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Capital Asset Pricing Model (CAPM)
- Dividend Discount Model (DDM)
- Return on Equity (ROE) since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Celgene Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
P/BV | = | Share price1, 2, 3 | ÷ | Book value per share1 (BVPS) | BVPS1 | = | Stockholders’ equity1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
Feb 7, 2018 | = | ÷ | = | ÷ | |||||||
Feb 10, 2017 | = | ÷ | = | ÷ | |||||||
Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
Mar 1, 2011 | = | ÷ | = | ÷ | |||||||
Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
Feb 20, 2008 | = | ÷ | = | ÷ | |||||||
Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
Mar 15, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Celgene Corp. Annual Report.
The analysis of the financial indicators over the period from March 2006 to February 2019 reveals several key trends and shifts in the company's market valuation and equity position.
- Share Price (US$)
- The share price generally exhibits an upward trend, starting at $20.50 in March 2006 and reaching a peak of $123.43 in February 2015. This represents a substantial increase over the nine-year span. Following this peak, the share price experiences a decline and stabilization, dropping to $89.71 by February 2019. The price trajectory includes periods of volatility, with noticeable increases from 2011 to 2015 and subsequent corrections thereafter.
- Book Value per Share (BVPS) (US$)
- The book value per share steadily increases from $0.92 in 2006 to $9.20 in 2018, indicating consistent growth in the company's net asset value per share. Despite minor fluctuations, including a slight decline from $8.15 in 2015 to $7.57 in 2016, the overall trend is positive, implying strengthening equity over time. By 2019, the BVPS marginally decreases to $8.77, suggesting a possible stabilization or slight contraction of net assets per share.
- Price-to-Book Value Ratio (P/BV)
- The P/BV ratio shows a declining trend from a very high 22.25 in 2006 to lower single-digit values between 2009 and 2011, indicating that the market price was much higher relative to the book value at the beginning and adjusted downwards as BVPS increased. From 2011 onwards, the ratio fluctuates between approximately 4 and 15, peaking around 15.14 in 2015, concurrent with the share price peak. Post-2015, the ratio moderately decreases and stabilizes around 10, which may suggest the market's reassessment of the company's valuation relative to its net assets, reflecting reduced growth expectations or market corrections.
In summary, the data reflects significant growth in share price and book value per share over the majority of the period, indicating positive investor sentiment and company equity expansion. However, the reduction in share price and P/BV ratio following 2015 implies market readjustment, possibly due to changing operational performance or external market conditions. The stabilization of these metrics towards the end suggests a new equilibrium in valuation relative to company fundamentals.
Comparison to Competitors
Celgene Corp. | AbbVie Inc. | Amgen Inc. | Bristol-Myers Squibb Co. | Danaher Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Feb 26, 2019 | |||||||||||||
Feb 7, 2018 | |||||||||||||
Feb 10, 2017 | |||||||||||||
Feb 11, 2016 | |||||||||||||
Feb 20, 2015 | |||||||||||||
Feb 13, 2014 | |||||||||||||
Feb 15, 2013 | |||||||||||||
Feb 22, 2012 | |||||||||||||
Mar 1, 2011 | |||||||||||||
Feb 18, 2010 | |||||||||||||
Feb 17, 2009 | |||||||||||||
Feb 20, 2008 | |||||||||||||
Feb 27, 2007 | |||||||||||||
Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Sector (Pharmaceuticals, Biotechnology & Life Sciences)
Celgene Corp., P/BV, long-term trends, comparison to sector (pharmaceuticals, biotechnology & life sciences)
Celgene Corp. | Pharmaceuticals, Biotechnology & Life Sciences | |
---|---|---|
Feb 26, 2019 | ||
Feb 7, 2018 | ||
Feb 10, 2017 | ||
Feb 11, 2016 | ||
Feb 20, 2015 | ||
Feb 13, 2014 | ||
Feb 15, 2013 | ||
Feb 22, 2012 | ||
Mar 1, 2011 | ||
Feb 18, 2010 | ||
Feb 17, 2009 | ||
Feb 20, 2008 | ||
Feb 27, 2007 | ||
Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
Comparison to Industry (Health Care)
Celgene Corp. | Health Care | |
---|---|---|
Feb 26, 2019 | ||
Feb 7, 2018 | ||
Feb 10, 2017 | ||
Feb 11, 2016 | ||
Feb 20, 2015 | ||
Feb 13, 2014 | ||
Feb 15, 2013 | ||
Feb 22, 2012 | ||
Mar 1, 2011 | ||
Feb 18, 2010 | ||
Feb 17, 2009 | ||
Feb 20, 2008 | ||
Feb 27, 2007 | ||
Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).